Context for United Therapeutics stock
United Therapeutics (UTHR) has drawn investor attention after recent trading saw the stock at a last close of US$549.47, with performance mixed over shorter horizons but stronger when looking at longer multiyear returns.
See our latest analysis for United Therapeutics.
Recent trading has been choppy, with the stock down 5.46% on a 1 month share price basis but up 13.28% over 3 months. The 1 year total shareholder return of 69.61% and 5 year total shareholder return of 214.43% reflect strong longer term momentum.
If you are comparing United Therapeutics with other potential opportunities in healthcare, it can be useful to see which peers are getting attention in fast growing niches via the 39 healthcare AI stocks
With United Therapeutics delivering solid multi year returns and trading at US$549.47, the key question now is whether the current price still leaves a margin of safety or if the market is already pricing in the company’s future growth.
Most Popular Narrative: 14.7% Undervalued
United Therapeutics' most followed narrative pegs fair value at about $644 per share, compared with the recent close of $549.47, which sets up a valuation built around future pulmonary programs and cash flows discounted at 7.08%.
The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine, which can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.
Want to see what kind of revenue path and profit margins have been baked into that fair value, and which future earnings multiple ties it all together, the full narrative lays out the complete playbook behind this $644 figure.
Result: Fair Value of $644 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the story could change quickly if key clinical trials disappoint or if competition in pulmonary arterial hypertension forces sharper pricing and share pressure than analysts expect.
Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.
Next Steps
If this sounds optimistic, it is because some investors see clear positives in the story. Move quickly, weigh the facts yourself, and then check the 4 key rewards.
Looking for more investment ideas?
If United Therapeutics is on your radar, do not stop here. Use the Simply Wall Street Screener to quickly spot other stocks that might fit your checklist.
- Target stability and income by reviewing companies built around reliable payouts with the 10 dividend fortresses
- Hunt for potential value by scanning quality stocks that trade below their estimated worth through the 46 high quality undervalued stocks
- Prioritize resilience by focusing on companies with steadier profiles using the 63 resilient stocks with low risk scores
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com